Literature DB >> 9637502

CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry.

A K Yi1, M Chang, D W Peckham, A M Krieg, R F Ashman.   

Abstract

Isolated murine splenic B cells undergo spontaneous apoptosis. Motifs containing unmethylated CpG dinucleotides in bacterial DNA or in synthetic oligodeoxynucleotides (ODN) are known to activate murine B cells. Now we show that ODN that induce spleen B cell cycle entry also inhibit spontaneous apoptosis in a sequence-specific fashion. Reversal of the CG to GC abolished activity. Methylation of the central cytosine decreased activity. When CpG is preceded by a cytosine or followed by a guanine, activity was abolished. Other substitutions at the same positions had no effect. Dose-response curves for apoptosis protection and G1 entry suggested that a uniform population of ODN recognition sites controlled downstream ODN effects. A CpG ODN with a nuclease-resistant phosphorothioate backbone (S-ODN) was also active, and increased the levels of c-myc, egr-1, c-jun, bclXL, and bax mRNA and c-Myc, c-Jun, Bax, and BclXL protein in spleen B cells. Levels of c-myb, myn, c-Ki-ras, and bcl2 mRNA remained unchanged. When protein synthesis was inhibited, at 16 h ODN-induced cell cycle entry was abolished and apoptosis protection was partially preserved. Under these conditions, c-Myc was still present, but c-Jun and BclXL were not detected. Our results suggest that CpG containing ODN motifs provide signals for both survival and cell cycle entry. Single base changes determine whether this signal proceeds through a rate-limiting step governing at least two steps in apoptosis (plasma membrane transition, DNA cleavage) and two phases of the cell cycle (G1 and S phase entry). This biologic action is associated with increased c-Myc, c-Jun, and BclXL expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637502

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  The response of human B lymphocytes to oligodeoxynucleotides.

Authors:  H Liang; P E Lipsky
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Signal transduction induced by immunostimulatory CpG DNA.

Authors:  A M Krieg
Journal:  Springer Semin Immunopathol       Date:  2000

Review 3.  Introduction to immunostimulatory DNA sequences.

Authors:  J Van Uden; E Raz
Journal:  Springer Semin Immunopathol       Date:  2000

Review 4.  Rescue of B cells from apoptosis by immune stimulatory CpG DNA.

Authors:  A M Krieg; A K Yi
Journal:  Springer Semin Immunopathol       Date:  2000

Review 5.  Activation of the immune system by bacterial CpG-DNA.

Authors:  Georg Häcker; Vanessa Redecke; Hans Häcker
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

6.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

7.  Impact of site-specific nucleobase deletions on the arthritogenicity of DNA.

Authors:  Jan L Bjersing; Andrej Tarkowski; Ekambar R Kandimalla; Helen Karlsson; Sudhir Agrawal; L Vincent Collins
Journal:  Inflammation       Date:  2004-06       Impact factor: 4.092

8.  Different sources of "help" facilitate the antibody response to hepatitis D virus delta antigen.

Authors:  Peter Seizer; Petra Riedl; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2004-11-10       Impact factor: 4.599

9.  TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production.

Authors:  Petar Lenert; Rachel Brummel; Elizabeth H Field; Robert F Ashman
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

10.  Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.

Authors:  Chuanlin Ding; Li Wang; Jose Marroquin; Jun Yan
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.